How to Help Your Patients Save Money on Hemady: A Provider's Guide to Savings Programs

Cost is one of the most common reasons patients with multiple myeloma skip or delay filling their medications — including Hemady. When patients can't afford their corticosteroid, it doesn't just create financial hardship; it can compromise the entire treatment regimen that depends on dexamethasone as a combination partner. As their provider, you're often best positioned to proactively connect your patients with savings resources before cost becomes a barrier. This guide covers every major savings mechanism available for Hemady in 2026, how to assess patient eligibility, and practical workflow suggestions to embed these resources into your prescribing process.

Understanding the Hemady Cost Landscape

Hemady's brand-name retail price ranges from approximately $240 to over $710 per prescription depending on quantity and pharmacy. There is no FDA-approved generic at the 20 mg tablet strength, so every Hemady patient is dealing with a brand-name price point. This creates meaningful cost burden for three distinct patient populations:

1. Commercially insured patients: May face high copays before deductible is met or if Hemady is placed on a non-preferred tier. Best addressed with the manufacturer savings card.
2. Medicare Part D patients: May experience high early-year costs before reaching the $2,100 annual out-of-pocket cap. Manufacturer copay cards cannot be used. Medicare-specific resources apply.
3. Uninsured or underinsured patients: Face full retail pricing. Generic dexamethasone is the most practical cost-management strategy, supplemented by foundation grants and access programs.

Savings Option 1: Hemady Patient Savings Program (Commercially Insured)

The Hemady Patient Savings Program, offered by Edenbridge Pharmaceuticals, is the primary savings mechanism for commercially insured patients. Eligible patients may pay as little as $0 per prescription.

• Program phone: 1-866-651-4128
• Enrollment: hemady.com/patient-and-caregiver-support — patient downloads and prints the savings card
• Eligibility: Commercially insured patients only — not valid for Medicare, Medicaid, or any other government-funded programs
• Application: Present the savings card at the specialty pharmacy with the prescription. Maximum savings limits and terms may apply; verify current program details.

Workflow recommendation: Include the Hemady savings program card information in your new myeloma patient onboarding packet. Your specialty pharmacy partner can also assist patients with enrollment at the time of first fill.

Savings Option 2: Medicare Part D — Helping Patients Navigate the 2026 Cap

For Medicare Part D beneficiaries, the most important development is the $2,100 annual out-of-pocket cap that went into effect in 2026 (following the $2,000 cap in 2025, per the Inflation Reduction Act). Once a patient reaches this cap, Part D pays 100% of covered medication costs for the rest of the benefit year. For patients using Hemady as part of an ongoing myeloma regimen, they may reach this cap relatively early in the year, after which Hemady and all other Part D-covered drugs become essentially cost-free.

For patients struggling with costs early in the year before reaching the cap:

• Medicare Prescription Payment Plan: Allows patients to spread their out-of-pocket costs over the year in monthly installments. This doesn't reduce the total but can make early-year costs manageable.
• Medicare Extra Help (Low Income Subsidy): Patients with limited income and resources may qualify for Extra Help, which dramatically reduces Part D premiums, deductibles, and copays. Encourage eligible patients to apply at SSA.gov or call 1-800-MEDICARE.
• State Pharmaceutical Assistance Programs (SPAPs): Some states offer additional drug cost assistance for Medicare beneficiaries. Check your state's SPAP status through CMS or NeedyMeds.

Savings Option 3: Disease-Specific Foundation Grants

For patients who don't qualify for manufacturer programs (Medicare/Medicaid) or can't afford cost-sharing, disease-specific foundations offer grants to cover medication costs. These are particularly valuable for patients with Medicare or Medicaid who can't use the manufacturer savings card:

• HealthWell Foundation (healthwellfoundation.org): Has a multiple myeloma fund. Check for current open enrollment status and income eligibility requirements.
• Patient Advocate Foundation (PAF) (patientadvocate.org): Co-Pay Relief Program provides direct financial aid to patients with certain diagnoses including multiple myeloma.
• International Myeloma Foundation (IMF) (myeloma.org): Financial assistance resources and patient services navigation.
• Multiple Myeloma Research Foundation (MMRF) (themmrf.org): Patient Navigation Center can connect patients with financial resources. Patient services hotline available.
• NeedyMeds (needymeds.org): Comprehensive database of patient assistance programs, disease-specific foundations, and state programs. Useful for identifying programs your patient may have missed.

Savings Option 4: Generic Dexamethasone — The Clinical Alternative

When no savings program reduces Hemady's cost to an affordable level, generic dexamethasone 4 mg tablets remain the definitive cost management strategy. At $5–$15 per month at virtually any retail pharmacy, and with identical clinical efficacy to Hemady, this is the most powerful "savings program" available — though it comes with the trade-off of increased pill burden (5–10 tablets per dose). For patients in extreme financial distress who cannot access any other program, this is a clinically appropriate solution that should not be dismissed as a lesser option from an oncology standpoint.

Document in the chart if generic substitution is being made due to cost/access barriers. This documentation can strengthen future PA requests for Hemady if the insurance plan requires step therapy through generic dexamethasone first.

Workflow Integration: Building Savings Into Your Practice

The most effective approach is to integrate savings conversations into your standard new patient onboarding:

1. Insurance assessment at first visit: Determine whether the patient has commercial, Medicare, Medicaid, or no insurance before prescribing Hemady. This determines which savings pathway applies.
2. Route prescription and savings card simultaneously: Have your specialty pharmacy partner handle both the prescription and the savings card enrollment for commercially insured patients at the time of first fill.
3. Include foundation contacts in patient education materials: Prepare a one-page resource sheet with HealthWell, PAF, MMRF, and IMF contact information for your myeloma patients.
4. Annual Medicare review: Each October, encourage Medicare patients to review their Part D plan during open enrollment (October 15 – December 7). Switching to a plan with Hemady on a lower tier can reduce annual costs.

Using medfinder for Providers to Reduce Access Burden

When cost issues delay or interrupt access to Hemady, patients may need to locate a different pharmacy that offers better pricing or participates in their savings program. medfinder for Providers helps patients find pharmacies near them that can fill their prescription, reducing the burden on your clinic staff to field calls about where to obtain the medication. Share medfinder.com with your patients as a self-service resource.

Summary of Savings Resources by Patient Type

• Commercially insured: Hemady Patient Savings Program (1-866-651-4128) → as low as $0
• Medicare Part D: $2,100 annual OOP cap; Extra Help for low-income; Medicare Prescription Payment Plan for cost spreading; state SPAPs; foundation grants (HealthWell, PAF)
• Uninsured/underinsured: Foundation grants (HealthWell, PAF, MMRF); Prescription Hope ($60/mo service); generic dexamethasone 4mg ($5–$15/month) as clinical alternative
• Medicaid: Medicaid formulary coverage varies by state; work with the Medicaid plan's specialty pharmacy; foundation grants may supplement